Program Description: 

Clinical trials of enhanced half-life FVIII and FIX – Peter Collins

Dr Collins will review clinical trials of enhanced half-life factor VIII and factor IX. He will offer a personal opinion on these agents could be introduced into routine clinical practice.

Experimental Therapies – Gary E. Gilbert

This presentation will cover the rationale for experimental therapies, including the untested assumptions and projections of the changing clinical standards for efficacy. It will then survey preclinical data for individual therapies and early clinical trial data. 

 
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and International Society on Thrombosis and Haemostasis. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
 
Designation of Credit Statement:
The Medical College of Wisconsin designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Please note: The course fee is $10.00 in addition to a $2.50 processing fee which is assessed for all electronic registrations.
 
More information and online registration:  http://academy.isth.org/isth/ 
 
 

 
Target audience: 

Physicians, trainees and fellows interested in learning about the new and upcoming treatments for hemophilia.

Learning objectives: 

At the conclusion of this activity, I will be able to:

  • Understand the rationale for experimental therapies and the untested assumptions that are likely to influence the degree of success.
  • Gain knowledge of the preclinical rationale and the early clinical data for experimental therapies that are in trials.
Faculty & credentials: 
Planning Committee:
Geoffrey Barnes, MD
Chris Ward, PhD
Stephen Watson, PhD
 
Speakers:
Peter Collins - "Clinical trials of enhanced half-life FVIII and FIX"
Gary Gilbert - "Experimental therapies"
 
Moderator:  David Lillicrap

 

All persons in control of content have NO relevant financial relationships to disclose with the exception of the following persons:  
 

Name

Company

Role

Geoffrey Barnes, MDPortolaConsulting
 Blue Cross Blue Shield of MichiganResearch
 BMS/PfizerResearch
Chris Ward, PhDBayerSpeaker
 Boehringer-IngelheimSpeaker, Advisory Board
 BMS/PfizerSpeaker, Advisory Board
Gary GilbertBaxaltaAdvisory Board
 BayerAdvisory Board
 Harvard Med School/VA HealthcareInventor
Peter CollinsNovo NordiskConsultant
 SobiConsultant
 BaxaltaConsultant

In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.

Contact

Name: 
Lacey Schmeidler, MA
Phone number: 
+1 (919) 929-3807
Email: 
lacey_schmeidler@isth.org
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Please login or register to take this course.